Polymers in Medicine

Polim. Med.
Scopus CiteScore: 3.5 (CiteScore Tracker 3.6)
Index Copernicus (ICV 2023) – 121.14
MEiN – 70
ISSN 0370-0747 (print)
ISSN 2451-2699 (online) 
Periodicity – biannual

Download PDF

Polymers in Medicine

2010, vol. 40, nr 2, April-June, p. 65–77

Publication type: original article

Language: Polish

Wpływ wielkocząsteczkowych substancji pomocniczych na proces dostępności farmaceutycznej środków leczniczych z modelowej postaci leku. Część I. Ex. Echinaceae aq. siccum w formulacjach o regulowanym czasie rozpadu (dezintegracja i uwalnianie)

The influence of polymeric excipients on the process of pharmaceutical availability of therapeutic agents from a model drug form. Part I. In formulations with controlled disintegration and release time

Michał Jakub Nachajski1,, Marian Mikołaj Zgoda1,

1 Zakład Technologii Postaci Leku, Katedra Farmacji Stosowanej, Uniwersytet Medyczny w Łodzi

Streszczenie

Przeprowadzono badania preformulacyjne nad możliwością wykorzystania Ex. Echinaceae aq siccum do wytworzenia szybko rozpadających się tabletek zawiesinowych, tabletek do ssania z udziałem kariostatycznych alkoholi cukrowych (mannitol, sorbitol), a przede wszystkim stałej modelowej postaci leku o regulowanym profilu uwalniania środków leczniczych zawartych w ekstrakcie. Oszacowano parametry morfologiczne wytworzonych tabletek, a ponadto zbadano profil uwalniania hydrofilowych środków leczniczych do modelowych płynów biorczych o różnej osmolarności (0,1 mol HCl 200 mOsm/l, płyn nawadniający interwencyjny hipotoniczny 143 mOsm/l, oraz płyn pediatryczny wyrównawczy 272 mOsm/l). Szczególną uwagę poświęcono technologicznemu ustaleniu wpływu hydrożelowej struktury Carbopoli na rzędowość procesu dyfuzji hydrofilowych środków leczniczych, z modelowej postaci leku (tabletki) do płynów biorczych o zmiennej wartości ciśnienia osmotycznego.

Abstract

Pre-formulation research was conducted on the application of Ex. Echinaceae aq. siccum in the production of a quickly disintegrating suspension tablet, a lozenge with kariostatic sugar alcohols (mannitol, sorbitol), and, above all, a solid drug form with controlled release of therapeutic agents included in the extract. Morphological parameters of tablets obtained in the course of experiment were estimated and the profiles of the release (diffusion) of hydrophilic therapeutic agents into model receptor fluids with varying values of osmolarity (0.1 mol HCl ~200mOsm/l, hypotonic hydrating fluid ~143 mOsm/l, and compensatory paediatric fluid ~272 mOsm/l) were examined. The study focused on the technological problem of determining the effect of hydrogel Carbopol structure on the ordering of diffusion of hydrophilic therapeutic agents from a model drug form (a tablet) into model fluids with variable osmolarity.

Słowa kluczowe

Carbopol, tabletki, Ex. Echinaceae aq. Siccum, celuloza mikrokrystaliczna

Key words

Carbopol, tablets, Ex. Echinaceae aq. Siccum, Microcrystalline cellulose

References (18)

  1. Luo W., Ang C. Y., gehring T. A., Heinze T. M., Lin L. J., Mattia A.: Determination of phenolic compounds in dietary supplements and tea blends containing Echinacea by liquid chromatography with coulometric electrochemical detection. J. AOAC int. (2003), March-April 86, (2), 202–208.
  2. Pomponio r., gotti r., Hudaib M., Cavrini V.: Analysis of phenolic acids by micellar electrokinetic chromatography: application to Echi­ nacea purpurea plant extracts J. of Chromatography A (2002), Vol. 945, i 1–2, 239–247.
  3. Osowski S., rostock M., bartsch H.H., Massing V.: Parmaceutical compatibility of different therapeutic Echinacea preparations. Forsch Komplementarmed Klass Naturheilkd., (2000), Vol. 7 (6), 294–300.
  4. Henneicke-von Zepelin H., Hentschel C., Schnitker J., Kohnen r., Kohler g., Wusteuberg P.: Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute virial respiratory tract infection) results of a randomized double blind, placebo controlled, multicentre study. Curr. Med. res. Opin., (1999), Vol. 15 (3), 214–227.
  5. Savickas A., bernatoniene J.: Optimalization of „Askoeziuofito” tablets., Medicina (Kanas)., (2005), Vol. 41 (3), 22–231.
  6. Hudson J., Vimalanthan S., Kang L., Livesey J., Arnanson J. T.: Characterisation of antivirial activities in Echinaceae root Preparations., Pharmaceutical biology., (2005), Vol. 43(J9) 790–796.
  7. Woelkart K.: Pharmacokinetics of the main alkamides after administration of theree different Echinacea purpurea preparations in humans. Planta Medica., (2008), Vol. 74 (J6) 651–656.
  8. Brown P. N., Paley L., roman M., Chan M.: Single-Laboratory validation of a method for the detection ond/or quantification of select alkaloids in golden scal supplements and raw materials by reversed Phase High-Performance Liquid Chromatography. Parmaceutical biology.,( 200), 8, Vol. 46 (J1/2), 135–144.
  9. Woelkart K., Marth E., Suter A., Schoop r., raggam r. b., Koidl C., Kleinhappi b., bauer r.: bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interactions with the immune system. int. J. Clin. Pharmacol. Ther., (2006), Vol. 44(9), 401–408.
  10. Vimalanathan S., Kang L., Amiguet V. T., Livesey J., Aranson J. T., Hudson J.: Echinacea purpura aerialcontain multiple antivirial compounds., Pharmaceutical biology. (2005), Vol. 43 (i9), 740–745.
  11. Spasov A. A., Ostrovskij O. V., Chernikov M. V. Wikman g.: Comparative controlled study of Andrographis paniculatafixed combination Kang Jang and Echinacea preparation as adjuvant, in the treatment o uncomplicated respiratory disease in children. Phytother.res., (2004), Vol. 18 (1), 47–53.
  12. Islam J., Carter r.: Use of Echinacea in upper respiratory tract infection., Southern Medical Journal., (2005), Vol. 98 (i3),.311–318.
  13. Agnew L. L., guffog S. P., Mathias A., Lehmann r. P., bone K. M., Watson K.: Echinacea intake induces an immune response through altered expression of leucocyte hsp70, increased with cell counts and improved erythrocyte antioxidant defences. J. Clin. Pharm. Therap., (2005), Vol 30 (i4), 363–369.
  14. Riniger J. A., Kickner S., Chiqurpati P., McLean A., Franck Z.: immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripherial blood mononuclear cells., i. Leukoc. biol., (2000), Vol. 68(4), 503–510.
  15. Wagner H., Jurcic K.: immunological studies of revitonil, a phytopharmaceutical containing Echinacea purpurea and glicyrhiza glabra root extract., Phytomedicine. (2002), Vol. 9 (5), 390– 397.
  16. Mattihias A., Addison r. S., Agnew L. L., bone K. M., Watson K., Lehmann r. P.: Comparsion of Echinacea alkylamide pharmacokinetics between liquid and tablet preparation., Phytomedicine (2007), Vol.14 (9), 587–590.
  17. Sterer N., Nuas Sh., Mizrahi b., goldenberg Ch., Weiss E., Domb A., Davidi M. P.: Oral malodor reduction by a palatal mucoadhesive tablet containing hebal formulation., J. Dentistry., (2008), Vol. 36 (i7), 535–539.
  18. Mathias A., Addison r. S., Peneman K. g., Dicknson r. g., bone K. M. Lehmann r. P.: Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion., Life Sciences., (2005), Vol. 77 (i16), 2018–2029.
© Wroclaw Medical University